NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.17 +0.21 (+2.64 %)
(As of 01/16/2019 12:54 PM ET)
Previous Close$7.96
Today's Range$7.92 - $8.40
52-Week Range$5.62 - $37.00
Volume121,355 shs
Average Volume485,571 shs
Market Capitalization$212.66 million
P/E Ratio-5.84
Dividend YieldN/A
Beta2.35
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

Receive DOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DOVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DOVA
CUSIPN/A
Phone919-748-5975

Debt

Current Ratio7.50
Quick Ratio7.40

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Book Value$2.38 per share
Price / Book3.43

Profitability

Net Income$-29,950,000.00
Net MarginsN/A
Return on Assets-50.15%

Miscellaneous

Employees33
Market Cap$212.66 million
OptionableOptionable

Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions

What is Dova Pharmaceuticals' stock symbol?

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

How were Dova Pharmaceuticals' earnings last quarter?

Dova Pharmaceuticals Inc (NASDAQ:DOVA) released its quarterly earnings results on Thursday, November, 8th. The company reported ($0.69) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.81) by $0.12. The firm had revenue of $2.93 million for the quarter, compared to analyst estimates of $2.66 million. View Dova Pharmaceuticals' Earnings History.

When is Dova Pharmaceuticals' next earnings date?

Dova Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for Dova Pharmaceuticals.

What price target have analysts set for DOVA?

5 equities research analysts have issued 1 year price targets for Dova Pharmaceuticals' stock. Their predictions range from $18.00 to $44.00. On average, they anticipate Dova Pharmaceuticals' share price to reach $32.3333 in the next year. This suggests a possible upside of 295.8% from the stock's current price. View Analyst Price Targets for Dova Pharmaceuticals.

What is the consensus analysts' recommendation for Dova Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dova Pharmaceuticals.

What are Wall Street analysts saying about Dova Pharmaceuticals stock?

Here are some recent quotes from research analysts about Dova Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. " (10/30/2018)
  • 2. Jefferies Financial Group Inc analysts commented, "About 6 weeks into Doptelet launch, DOVA has been pleased with reimbursement levels (not seeing pushback from payers); plans to provide some key metrics, including % Rx getting reimbursed by payers on 2Q18 call." (7/15/2018)

Has Dova Pharmaceuticals been receiving favorable news coverage?

Media headlines about DOVA stock have been trending positive on Wednesday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an effect on the stock's share price in the immediate future.

Who are some of Dova Pharmaceuticals' key competitors?

Who are Dova Pharmaceuticals' key executives?

Dova Pharmaceuticals' management team includes the folowing people:
  • Dr. Lee F. Allen, Chief Medical Officer (Age 67)
  • Dr. David S. Zaccardelli, Pres & CEO (Age 54)
  • Mr. Mark W. Hahn, CFO & Sec. (Age 56)
  • Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)
  • Mr. Jason Hoitt, Chief Commercial Officer

When did Dova Pharmaceuticals IPO?

(DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

How do I buy shares of Dova Pharmaceuticals?

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dova Pharmaceuticals' stock price today?

One share of DOVA stock can currently be purchased for approximately $8.17.

How big of a company is Dova Pharmaceuticals?

Dova Pharmaceuticals has a market capitalization of $212.66 million. The company earns $-29,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Dova Pharmaceuticals employs 33 workers across the globe.

What is Dova Pharmaceuticals' official website?

The official website for Dova Pharmaceuticals is http://www.dova.com.

How can I contact Dova Pharmaceuticals?

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]


MarketBeat Community Rating for Dova Pharmaceuticals (NASDAQ DOVA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  281
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel